Correction to: A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling
Following the publication of the original article [1], the authors identified some minor errors in image-typesetting in Figs. 2 and 7; specifically the DAPI image panels in Fig. 2d, and Fig. 7a. The corrected images have been provided here. The correction has no impact on the results or conclusions of the study.
Fig. 2
Characterization the existence and subcellular distribution of circPPP1R12A in CC cells and tissues. a The divergent primers detected circPPP1R12A in cDNA but not in gDNA. b Real-time PCR analysis of circPPP1R12A and linear PPP1R12A mRNA after treatment with RNase R in HCT-116 cells showed that circPPP1R12A was resistant to RNase R treatment. The sub-cellular distribution of circPPP1R12A was mostly present in the cytoplasm by the nuclear mass separation assay (c) and FISH (d). e The level of circPPP1R12A was analyzed by in situ hybridization on CC tissue microarray, showing that circPPP1R12A was up-regulated in CC tissues compared with normal tissues, and such up-regulation was positively correlated with larger tumors and a higher TNM stage. f Kaplan–Meier analysis of the correlation between circPPP1R12A expression and overall survival showed that patients with higher levels of circPPP1R12A had a significantly shorter overall survival. ***P < 0.001
Fig. 7
CircPPP1R12A-73aa, not circPPP1R12A, promotes the in vivo tumorigenicity ability of CC using nude mice xenografts. a Representative nude mice xenograft formed by the indicated cells. b Statistical analysis of xenograft tumor growth formed by the indicated cells. c Tumor weights of the indicated cells. d Bioluminescent Imaging (BLI) of mice as indicated (Red arrow indicates the metastatic site in BLI of mice). The images were representative of the data. Counts are photons detected. Images were captured with a 5 min exposure. Whole body flux (photons/sec) quantification of mice injected with different 1 × 105 DLD-1 cells at day 25 (n = 5). The data are represented as the means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001. The red * indicated the Lv-flag-circPPP1R12A-WT group, The blue * indicated the Lv-circPPP1R12A-73aa group
×
×
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction to: A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling
verfasst von
Xiao Zheng Lujun Chen You Zhou Qi Wang Zhuojun Zheng Bin Xu Chen Wu Qi Zhou Wenwei Hu Changping Wu Jingting Jiang
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
